Aprea Therapeutics, Inc. (NasdaqCM: APRE)
Health Care · Biotechnology · US
$0.58
-3.34% today · -64.6% 1Y
Aprea Therapeutics, Inc. (NasdaqCM: APRE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.36M and employs 8 people.
Over the last twelve months the share price has lost 64.6%, trading between 0.55 and 1.69.
Tweenvest scores Aprea Therapeutics, Inc. across four factors: quality 35/100, value 11/100. Its strongest factor is quality.
APRE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.36M
- Revenue (TTM)
- $5.18K
- P/E
- —
- EPS
- -0.60
- Dividend yield
- —
- Beta (5Y)
- 1.63
- 52-week high
- $1.69
- 52-week low
- $0.55
- Avg volume (3M)
- —
- Shares outstanding
- 12.59M
- Employees
- 8
- Next earnings
- —
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
- ISIN
- US03836J2015
- Listed since
- Oct 3, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Soligenix, Inc.NasdaqCM: SNGX | $7.69M | $0.35 | -2.89% |
| Immuron LimitedASX: IMC | $7.64M | AU$0.03 | -24.44% |
| Oncotelic Therapeutics, Inc.OTCPK: OTLC | $7.59M | $0.02 | -20.19% |
| Ascelia Pharma AB (publ)OM: ACE | $7.58M | Skr0.56 | -34.65% |
| Exicure, Inc.NasdaqCM: XCUR | $7.33M | $1.12 | +6.67% |
| Oncodesign Precision Medicine Société anonymeENXTPA: ALOPM | $7.30M | €0.34 | +3.33% |
| Prostatype Genomics AB (publ)OM: PROGEN | $7.26M | Skr0.10 | +13.29% |
| Zeo ScientifiX, Inc.OTCPK: ZEOX | $7.14M | $0.91 | -23.11% |
Figures last refreshed Oct 18, 2026.